SRR1331534
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.351
- SPERMATOGENESIS+0.339
- PANCREAS_BETA_CELLS+0.154
- APICAL_SURFACE+0.147
- MYOGENESIS+0.124
- ALLOGRAFT_REJECTION+0.051
- OXIDATIVE_PHOSPHORYLATION+0.047
- APICAL_JUNCTION-0.015
- COAGULATION-0.017
- KRAS_SIGNALING_UP-0.031
Top 10 suppressed
- NOTCH_SIGNALING-0.492
- UNFOLDED_PROTEIN_RESPONSE-0.486
- MTORC1_SIGNALING-0.472
- TNFA_SIGNALING_VIA_NFKB-0.465
- G2M_CHECKPOINT-0.448
- E2F_TARGETS-0.442
- MYC_TARGETS_V1-0.439
- PROTEIN_SECRETION-0.430
- IL6_JAK_STAT3_SIGNALING-0.406
- ANDROGEN_RESPONSE-0.389
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1355262 | GTEX | — | 0.971 |
| 2 | SRR1321462 | GTEX | — | 0.965 |
| 3 | SRR1341008 | GTEX | — | 0.950 |
| 4 | SRR1365987 | GTEX | — | 0.941 |
| 5 | SRR1470397 | GTEX | — | 0.940 |
| 6 | SRR1357189 | GTEX | — | 0.939 |
| 7 | SRR1313951 | GTEX | — | 0.936 |
| 8 | SRR602927 | GTEX | — | 0.934 |
| 9 | SRR1403831 | GTEX | — | 0.934 |
| 10 | MNG599 | — | — | 0.933 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.351 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.339 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.154 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.147 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.124 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.051 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.047 | Remibrutinib | — uncovered |